Key result
COMPASS-31 screening detects autonomic neuropathy in ~11% of primary care diabetes patients.
Why the study?
Diabetes autonomic neuropathy impacts mortality, and guidelines recommend early recognition, prompting assessment of its proportion and associated factors in primary health centres.
What is the prevalence of autonomic neuropathy using the COMPASS-31 scale among diabetes patients in primary health centres?
Cross-Sectional (n=303)
Yes
What is the prevalence of autonomic neuropathy using the COMPASS-31 scale among diabetes patients in primary health centres?
Approximately one in ten diabetes patients in primary care screened positive for autonomic neuropathy using the COMPASS-31 scale, highlighting the potential utility of routine screening in this setting.
May support COMPASS-31 screening feasibility in primary care diabetes; hypothesis-generating pending validation studies.
Background: Diabetes autonomic neuropathy (DAN) is a complication of diabetes which has direct implications on the mortality of diabetes patients. American Diabetes Association (ADA-2017) guidelines recommend early recognition and treatment of DAN. In this regard, we conducted a study among diabetic patients treated in the selected PHCs of Puducherry to determine the proportion with DAN and to assess the factors associated with DAN.Methods: A cross-sectional analytical study was conducted among diabetics and information on socio-demographic details, morbidity and behavioural risk factors were elicited using semi-structured interview schedule. The COMPASS-31 questionnaire was administered to assess the autonomic neuropathy symptoms. The data was captured using EpiCollect mobile app and analysed using Stata 12.0 software. The proportion of DAN was expressed as percentage with 95% confidence interval. The association between independent factors and DAN was assessed using multivariate generalized linear models. The prevalence ratio with 95% CI was used to express the strength of association.Results: Of the total 303 individuals with diabetes, 32 {10.6% (95% CI: 7.3%-14.6%)} were screened positive for autonomic neuropathy using COMPASS-31 scale. The number of individuals with diabetes who needed to be screened (NNS) for finding one with autonomic neuropathy was 10 (303/32).Conclusions: One in ten individuals with diabetes was screened positive for autonomic neuropathy. With good yield, there is need for including autonomic neuropathy screening as a component in the comprehensive care provided to diabetes patients in the primary health centres.
No takes yet. Share an insight, caveat, or question.
Thekkur et al. (2019) conducted a cross-sectional in Diabetes (n=303). COMPASS-31 screening was evaluated on Screened positive for autonomic neuropathy using COMPASS-31 scale (95% CI 7.3-14.6). Screening with the COMPASS-31 scale identified autonomic neuropathy in 10.6% of individuals with diabetes treated at primary health centers, yielding a number needed to screen of 10.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: